Edgewise Therapeutics Inc. (EWTX) NASDAQ
$16.11 0.46 (2.94%)
Market Cap: $1.46B
As of 04/24/24 04:00 PM EDT. Market closed.
Edgewise Therapeutics Inc. (EWTX)
NASDAQ
$16.11
0.46 (2.94%)
Market Cap: $1.46B
As of 04/24/24 04:00 PM EDT. Market closed.
Add to Portfolio
edgewise therapeutics is a biotechnology company focused on developing novel therapies for diseases involving skeletal muscle. the company is headquartered in boulder, co and received its series a financing from ... read more
COMPANY PROFILE
Sector
Professional, Scientific, and Technical Services
Industry
Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
Sector
Professional, Scientific, and Technical Services
Industry
Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
Full Time Employees
79
Address
.
PRICE CHART FOR EDGEWISE THERAPEUTICS INC
From:
To:
NEWS
INSIDEARBITRAGE ARTICLES
KEY STATS
Open
$15.78
Previous Close
$15.65
Days Range
$15.11 - $15.85
52 week range
$5.12 - $20.69
Volume
526,410
Avg. Volume (30 days)
528,863
Market Cap
$1.46B
Dividend Yield
-
P/E
-
Shares Outstanding
93,110,623
Open
$15.78
Previous Close
$15.65
Days Range
$15.11 - $15.85
52 week range
$5.12 - $20.69
Volume
526,410
Avg. Volume (30 days)
528,863
Market Cap
$1.46B
Dividend Yield
-
P/E
-
Shares Outstanding
93,110,623
FINANCIAL STATEMENTS FOR EDGEWISE THERAPEUTICS INC
LOADING...
INSIDER TRANSACTIONS FOR EDGEWISE THERAPEUTICS INC
Owner | Relationship | Date | Transaction | Cost | # Shares | Value($) | Total Shares | Form 4 |
MOORE JOHN R | General Counsel | Feb 07, 2024 | Option Exercise | $1.93 | 17,993 | 34,726 | 17,993 | Feb 09, 2024, 05:43 PM |
MOORE JOHN R | General Counsel | Feb 09, 2024 | Option Exercise | $1.93 | 8,029 | 15,496 | 8,029 | Feb 09, 2024, 05:43 PM |
MOORE JOHN R | General Counsel | Feb 08, 2024 | Option Exercise | $1.93 | 3,813 | 7,359 | 3,813 | Feb 09, 2024, 05:43 PM |
MOORE JOHN R | General Counsel | Feb 07, 2024 | Sale | $20.00 | 17,993 | 359,864 | 0 | Feb 09, 2024, 05:43 PM |
MOORE JOHN R | General Counsel | Feb 09, 2024 | Sale | $20.01 | 8,029 | 160,657 | 0 | Feb 09, 2024, 05:43 PM |
MOORE JOHN R | General Counsel | Feb 08, 2024 | Sale | $20.01 | 3,813 | 76,285 | 0 | Feb 09, 2024, 05:43 PM |
Derakhshan Behrad | Chief Business Officer | Feb 07, 2024 | Option Exercise | $1.93 | 600 | 1,158 | 7,620 | Feb 09, 2024, 05:42 PM |
Derakhshan Behrad | Chief Business Officer | Feb 09, 2024 | Option Exercise | $1.93 | 4,800 | 9,264 | 11,820 | Feb 09, 2024, 05:42 PM |
Derakhshan Behrad | Chief Business Officer | Feb 08, 2024 | Option Exercise | $1.93 | 4,600 | 8,878 | 11,620 | Feb 09, 2024, 05:42 PM |
Derakhshan Behrad | Chief Business Officer | Feb 09, 2024 | Sale | $20.04 | 4,800 | 96,209 | 7,020 | Feb 09, 2024, 05:42 PM |
Derakhshan Behrad | Chief Business Officer | Feb 08, 2024 | Sale | $20.01 | 4,600 | 92,049 | 7,020 | Feb 09, 2024, 05:42 PM |
Derakhshan Behrad | Chief Business Officer | Feb 07, 2024 | Sale | $20.00 | 600 | 12,000 | 7,020 | Feb 09, 2024, 05:42 PM |
Carruthers R Michael | Chief Financial Officer | Jan 23, 2024 | Option Exercise | $1.93 | 90,000 | 173,700 | 119,024 | Jan 25, 2024, 04:46 PM |
Carruthers R Michael | Chief Financial Officer | Jan 23, 2024 | Sale | $15.78 | 90,000 | 1,419,759 | 29,024 | Jan 25, 2024, 04:46 PM |
Thompson Peter A. | Director | Jan 23, 2024 | Buy | $11.00 | 454,545 | 4,999,995 | 14,436,497 | Jan 25, 2024, 04:32 PM |
ORBIMED ADVISORS LLC | Director | Jan 23, 2024 | Buy | $11.00 | 454,545 | 4,999,995 | 14,436,497 | Jan 25, 2024, 04:28 PM |
Fox Jonathan C | Director | Dec 26, 2023 | Buy | $9.30 | 10,857 | 100,958 | 10,857 | Dec 28, 2023, 04:39 PM |
MOORE JOHN R | General Counsel | Dec 27, 2023 | Sale | $10.50 | 8,497 | 89,219 | 0 | Dec 28, 2023, 04:39 PM |
Russell Alan J | Chief Scientific Officer | Dec 26, 2023 | Sale | $9.33 | 172,585 | 1,610,097 | 3,606 | Dec 28, 2023, 04:38 PM |
Carruthers R Michael | Chief Financial Officer | Jun 22, 2023 | Option Exercise | $0.71 | 10,000 | 7,100 | 29,024 | Jun 26, 2023, 04:28 PM |
Derakhshan Behrad | Chief Business Officer | May 02, 2023 | Sale | $8.90 | 1,747 | 15,557 | 7,020 | May 03, 2023, 06:26 PM |
MOORE JOHN R | General Counsel | May 02, 2023 | Sale | $8.90 | 1,897 | 16,893 | 6,565 | May 03, 2023, 06:26 PM |
Carruthers R Michael | Chief Financial Officer | May 02, 2023 | Sale | $8.90 | 1,336 | 11,897 | 16,126 | May 03, 2023, 06:26 PM |
Russell Alan J | Chief Scientific Officer | May 02, 2023 | Sale | $8.90 | 1,602 | 14,266 | 176,191 | May 03, 2023, 06:26 PM |
Donovan Joanne M. | CMO | May 02, 2023 | Sale | $8.90 | 3,254 | 28,977 | 9,960 | May 03, 2023, 06:25 PM |
KOCH KEVIN | President and CEO | May 02, 2023 | Sale | $8.90 | 3,203 | 28,522 | 7,213 | May 03, 2023, 06:25 PM |
MOORE JOHN R | General Counsel | Oct 03, 2022 | Option Exercise | $1.93 | 4,730 | 9,129 | 7,730 | Oct 05, 2022, 04:42 PM |
MOORE JOHN R | General Counsel | Oct 03, 2022 | Sale | $9.76 | 4,730 | 46,155 | 3,000 | Oct 05, 2022, 04:42 PM |
Thompson Peter A. | Director | Sep 16, 2022 | Buy | $10.32 | 484,496 | 4,999,999 | 13,981,952 | Sep 16, 2022, 04:34 PM |
ORBIMED ADVISORS LLC | Director | Sep 16, 2022 | Buy | $10.32 | 484,496 | 4,999,999 | 13,981,952 | Sep 16, 2022, 04:31 PM |
Novo Holdings A/S | 10% Owner | Sep 14, 2022 | Buy | $10.32 | 484,496 | 4,999,999 | 6,071,703 | Sep 16, 2022, 02:35 PM |
MOORE JOHN R | General Counsel | Sep 06, 2022 | Option Exercise | $1.93 | 4,730 | 9,129 | 7,730 | Sep 08, 2022, 04:16 PM |
MOORE JOHN R | General Counsel | Sep 06, 2022 | Sale | $10.91 | 4,730 | 51,598 | 5,351 | Sep 08, 2022, 04:16 PM |
MOORE JOHN R | General Counsel | Aug 03, 2022 | Option Exercise | $1.34 | 9,232 | 12,325 | 12,232 | Aug 05, 2022, 04:12 PM |
MOORE JOHN R | General Counsel | Aug 03, 2022 | Sale | $9.31 | 9,232 | 85,921 | 3,000 | Aug 05, 2022, 04:12 PM |
MOORE JOHN R | General Counsel | Jul 05, 2022 | Option Exercise | $1.26 | 8,186 | 10,307 | 11,186 | Jul 07, 2022, 04:23 PM |
MOORE JOHN R | General Counsel | Jul 06, 2022 | Option Exercise | $1.93 | 1,046 | 2,019 | 4,046 | Jul 07, 2022, 04:23 PM |
MOORE JOHN R | General Counsel | Jul 05, 2022 | Sale | $8.35 | 8,186 | 68,329 | 3,000 | Jul 07, 2022, 04:23 PM |
MOORE JOHN R | General Counsel | Jul 06, 2022 | Sale | $8.54 | 1,046 | 8,928 | 3,000 | Jul 07, 2022, 04:23 PM |
MOORE JOHN R | General Counsel | Jun 16, 2022 | Option Exercise | $1.93 | 14,722 | 28,413 | 17,722 | Jun 21, 2022, 06:50 PM |
MOORE JOHN R | General Counsel | Jun 21, 2022 | Option Exercise | $1.40 | 31,078 | 43,501 | 34,078 | Jun 21, 2022, 06:50 PM |
MOORE JOHN R | General Counsel | Jun 17, 2022 | Option Exercise | $1.93 | 22,127 | 42,705 | 25,127 | Jun 21, 2022, 06:50 PM |
MOORE JOHN R | General Counsel | Jun 21, 2022 | Sale | $7.29 | 31,078 | 226,695 | 3,000 | Jun 21, 2022, 06:50 PM |
MOORE JOHN R | General Counsel | Jun 17, 2022 | Sale | $6.62 | 22,127 | 146,434 | 3,000 | Jun 21, 2022, 06:50 PM |
MOORE JOHN R | General Counsel | Jun 16, 2022 | Sale | $6.17 | 14,722 | 90,805 | 3,000 | Jun 21, 2022, 06:50 PM |
MOORE JOHN R | General Counsel | Jun 13, 2022 | Option Exercise | $0.71 | 4,093 | 2,906 | 7,093 | Jun 15, 2022, 06:39 PM |
MOORE JOHN R | General Counsel | Jun 15, 2022 | Option Exercise | $0.75 | 18,660 | 13,962 | 21,660 | Jun 15, 2022, 06:39 PM |
MOORE JOHN R | General Counsel | Jun 14, 2022 | Option Exercise | $0.71 | 3,628 | 2,576 | 6,628 | Jun 15, 2022, 06:39 PM |
MOORE JOHN R | General Counsel | Jun 15, 2022 | Sale | $6.11 | 18,660 | 114,020 | 21,075 | Jun 15, 2022, 06:39 PM |
MOORE JOHN R | General Counsel | Jun 14, 2022 | Sale | $6.02 | 3,628 | 21,855 | 3,000 | Jun 15, 2022, 06:39 PM |
MOORE JOHN R | General Counsel | Jun 13, 2022 | Sale | $6.01 | 4,093 | 24,582 | 3,000 | Jun 15, 2022, 06:39 PM |
MOORE JOHN R | General Counsel | Jun 08, 2022 | Option Exercise | $0.71 | 12,566 | 8,922 | 15,566 | Jun 10, 2022, 06:34 PM |
MOORE JOHN R | General Counsel | Jun 10, 2022 | Option Exercise | $0.71 | 7,125 | 5,059 | 10,125 | Jun 10, 2022, 06:34 PM |
MOORE JOHN R | General Counsel | Jun 09, 2022 | Option Exercise | $0.71 | 7,615 | 5,407 | 10,615 | Jun 10, 2022, 06:34 PM |
MOORE JOHN R | General Counsel | Jun 10, 2022 | Sale | $6.05 | 7,125 | 43,120 | 3,000 | Jun 10, 2022, 06:34 PM |
MOORE JOHN R | General Counsel | Jun 09, 2022 | Sale | $6.49 | 7,615 | 49,397 | 3,000 | Jun 10, 2022, 06:34 PM |
MOORE JOHN R | General Counsel | Jun 08, 2022 | Sale | $6.63 | 12,566 | 83,362 | 3,000 | Jun 10, 2022, 06:34 PM |
MOORE JOHN R | General Counsel | Jun 07, 2022 | Option Exercise | $0.78 | 18,123 | 14,054 | 20,150 | Jun 07, 2022, 07:03 PM |
MOORE JOHN R | General Counsel | Jun 06, 2022 | Option Exercise | $1.93 | 13,934 | 26,893 | 16,934 | Jun 07, 2022, 07:03 PM |
MOORE JOHN R | General Counsel | Jun 03, 2022 | Option Exercise | $1.93 | 15,230 | 29,394 | 18,230 | Jun 07, 2022, 07:03 PM |
MOORE JOHN R | General Counsel | Jun 07, 2022 | Sale | $6.61 | 18,123 | 119,702 | 3,000 | Jun 07, 2022, 07:03 PM |
MOORE JOHN R | General Counsel | Jun 06, 2022 | Sale | $6.03 | 13,934 | 84,085 | 3,000 | Jun 07, 2022, 07:03 PM |
MOORE JOHN R | General Counsel | Jun 03, 2022 | Sale | $6.05 | 15,230 | 92,198 | 3,000 | Jun 07, 2022, 07:03 PM |
Carruthers R Michael | Chief Financial Officer | May 23, 2022 | Option Exercise | $0.71 | 9,000 | 6,390 | 12,000 | May 25, 2022, 06:11 PM |
ORBIMED ADVISORS LLC | Director | May 18, 2022 | Buy | $7.21 | 138,000 | 994,980 | 13,497,456 | May 20, 2022, 04:38 PM |
Thompson Peter A. | Director | May 18, 2022 | Buy | $7.21 | 138,000 | 994,980 | 13,497,456 | May 20, 2022, 04:32 PM |
MOORE JOHN R | General Counsel | May 16, 2022 | Sale | $7.42 | 10,800 | 80,146 | 3,000 | May 18, 2022, 05:15 PM |
MOORE JOHN R | General Counsel | Jan 21, 2022 | Option Exercise | $0.71 | 5,400 | 3,834 | 12,362 | Jan 25, 2022, 06:50 PM |
MOORE JOHN R | General Counsel | Dec 28, 2021 | Option Exercise | $0.71 | 5,400 | 3,834 | 6,962 | Dec 30, 2021, 05:51 PM |
Russell Alan J | Chief Scientific Officer | Nov 30, 2021 | Option Exercise | $0.22 | 172,585 | 37,815 | 172,585 | Dec 01, 2021, 06:20 PM |
Russell Alan J | Chief Scientific Officer | Nov 15, 2021 | Sale | $19.11 | 479 | 9,155 | 38 | Nov 17, 2021, 06:05 PM |
Russell Alan J | Chief Scientific Officer | Nov 12, 2021 | Sale | $19.51 | 8,562 | 167,074 | 479 | Nov 12, 2021, 05:24 PM |
Russell Alan J | Chief Scientific Officer | Nov 11, 2021 | Sale | $19.93 | 19,276 | 384,238 | 12,722 | Nov 12, 2021, 05:24 PM |
Russell Alan J | Chief Scientific Officer | Nov 10, 2021 | Sale | $19.73 | 12,326 | 243,170 | 28,897 | Nov 12, 2021, 05:24 PM |
Russell Alan J | Chief Scientific Officer | Nov 09, 2021 | Sale | $20.09 | 29,576 | 594,306 | 53,355 | Nov 12, 2021, 05:24 PM |
Russell Alan J | Chief Scientific Officer | Nov 05, 2021 | Sale | $19.62 | 13,042 | 255,907 | 92,272 | Nov 08, 2021, 07:11 PM |
Russell Alan J | Chief Scientific Officer | Nov 04, 2021 | Sale | $19.76 | 7,392 | 146,092 | 92,278 | Nov 08, 2021, 07:11 PM |
Russell Alan J | Chief Scientific Officer | Nov 08, 2021 | Sale | $20.16 | 9,017 | 181,824 | 70,219 | Nov 08, 2021, 07:11 PM |
Russell Alan J | Chief Scientific Officer | Nov 03, 2021 | Sale | $18.18 | 26,184 | 476,096 | 105,032 | Nov 03, 2021, 07:00 PM |
Russell Alan J | Chief Scientific Officer | Nov 02, 2021 | Sale | $17.43 | 17,519 | 305,360 | 125,854 | Nov 03, 2021, 07:00 PM |
Russell Alan J | Chief Scientific Officer | Nov 01, 2021 | Sale | $18.02 | 469 | 8,454 | 143,373 | Nov 03, 2021, 07:00 PM |
Russell Alan J | Chief Scientific Officer | Oct 14, 2021 | Sale | $18.18 | 5,749 | 104,517 | 145,275 | Oct 18, 2021, 07:48 PM |
Russell Alan J | Chief Scientific Officer | Oct 15, 2021 | Sale | $18.12 | 1,433 | 25,966 | 143,968 | Oct 18, 2021, 07:48 PM |
Russell Alan J | Chief Scientific Officer | Oct 11, 2021 | Sale | $18.02 | 1,270 | 22,885 | 151,024 | Oct 13, 2021, 06:51 PM |
Russell Alan J | Chief Scientific Officer | Oct 08, 2021 | Sale | $18.15 | 5,902 | 107,121 | 152,294 | Oct 08, 2021, 06:00 PM |
Russell Alan J | Chief Scientific Officer | Oct 07, 2021 | Sale | $18.56 | 13,018 | 241,614 | 158,196 | Oct 08, 2021, 06:00 PM |
Russell Alan J | Chief Scientific Officer | Oct 06, 2021 | Sale | $18.03 | 2,108 | 38,007 | 171,214 | Oct 08, 2021, 06:00 PM |
Russell Alan J | Chief Scientific Officer | Oct 04, 2021 | Sale | $18.00 | 100 | 1,800 | 178,726 | Oct 05, 2021, 06:33 PM |
Russell Alan J | Chief Scientific Officer | Oct 01, 2021 | Sale | $18.00 | 274 | 4,932 | 178,826 | Oct 05, 2021, 06:33 PM |
Russell Alan J | Chief Scientific Officer | Oct 05, 2021 | Sale | $18.26 | 5,404 | 98,677 | 173,322 | Oct 05, 2021, 06:33 PM |
Russell Alan J | Chief Scientific Officer | Sep 29, 2021 | Sale | $16.86 | 11,844 | 199,730 | 179,718 | Sep 30, 2021, 07:16 PM |
Russell Alan J | Chief Scientific Officer | Sep 28, 2021 | Sale | $17.30 | 14,610 | 252,753 | 190,944 | Sep 30, 2021, 07:16 PM |
Russell Alan J | Chief Scientific Officer | Sep 27, 2021 | Sale | $17.98 | 11,611 | 208,774 | 205,571 | Sep 27, 2021, 07:32 PM |
Russell Alan J | Chief Scientific Officer | Sep 24, 2021 | Sale | $18.16 | 20,100 | 365,016 | 217,165 | Sep 27, 2021, 07:32 PM |
Russell Alan J | Chief Scientific Officer | Sep 23, 2021 | Sale | $18.54 | 26,835 | 497,632 | 242,337 | Sep 27, 2021, 07:32 PM |
ROOT JONATHAN D | Director | Mar 30, 2021 | Buy | $16.00 | 15,625 | 250,000 | 15,625 | Mar 31, 2021, 07:12 PM |
Thompson Peter A. | Director | Mar 30, 2021 | Buy | $16.00 | 359,375 | 5,750,000 | 13,359,456 | Mar 31, 2021, 07:11 PM |
ORBIMED ADVISORS LLC | Director | Mar 30, 2021 | Buy | $16.00 | 359,375 | 5,750,000 | 13,359,456 | Mar 31, 2021, 07:10 PM |
Novo Holdings A/S | 10% Owner | Mar 30, 2021 | Buy | $16.00 | 625,000 | 10,000,000 | 5,587,207 | Mar 31, 2021, 04:36 PM |
Flynn James E | 10% Owner | Mar 30, 2021 | Buy | $16.00 | 625,000 | 10,000,000 | 3,933,137 | Mar 30, 2021, 03:42 PM |
Load More Insider Transactions
Buy
Sale
Option Exercise
Owner | Relationship | Date | Value($) |
MOORE JOHN R | General Counsel | 02/07/2024 | 34,726 |
MOORE JOHN R | General Counsel | 02/09/2024 | 15,496 |
MOORE JOHN R | General Counsel | 02/08/2024 | 7,359 |
MOORE JOHN R | General Counsel | 02/07/2024 | 359,864 |
MOORE JOHN R | General Counsel | 02/09/2024 | 160,657 |
MOORE JOHN R | General Counsel | 02/08/2024 | 76,285 |
Derakhshan Behrad | Chief Business Officer | 02/07/2024 | 1,158 |
Derakhshan Behrad | Chief Business Officer | 02/09/2024 | 9,264 |
Derakhshan Behrad | Chief Business Officer | 02/08/2024 | 8,878 |
Derakhshan Behrad | Chief Business Officer | 02/09/2024 | 96,209 |
Derakhshan Behrad | Chief Business Officer | 02/08/2024 | 92,049 |
Derakhshan Behrad | Chief Business Officer | 02/07/2024 | 12,000 |
Carruthers R Michael | Chief Financial Officer | 01/23/2024 | 173,700 |
Carruthers R Michael | Chief Financial Officer | 01/23/2024 | 1,419,759 |
Thompson Peter A. | Director | 01/23/2024 | 4,999,995 |
ORBIMED ADVISORS LLC | Director | 01/23/2024 | 4,999,995 |
Fox Jonathan C | Director | 12/26/2023 | 100,958 |
MOORE JOHN R | General Counsel | 12/27/2023 | 89,219 |
Russell Alan J | Chief Scientific Officer | 12/26/2023 | 1,610,097 |
Carruthers R Michael | Chief Financial Officer | 06/22/2023 | 7,100 |
Derakhshan Behrad | Chief Business Officer | 05/02/2023 | 15,557 |
MOORE JOHN R | General Counsel | 05/02/2023 | 16,893 |
Carruthers R Michael | Chief Financial Officer | 05/02/2023 | 11,897 |
Russell Alan J | Chief Scientific Officer | 05/02/2023 | 14,266 |
Donovan Joanne M. | CMO | 05/02/2023 | 28,977 |
KOCH KEVIN | President and CEO | 05/02/2023 | 28,522 |
MOORE JOHN R | General Counsel | 10/03/2022 | 9,129 |
MOORE JOHN R | General Counsel | 10/03/2022 | 46,155 |
Thompson Peter A. | Director | 09/16/2022 | 4,999,999 |
ORBIMED ADVISORS LLC | Director | 09/16/2022 | 4,999,999 |
Novo Holdings A/S | 10% Owner | 09/14/2022 | 4,999,999 |
MOORE JOHN R | General Counsel | 09/06/2022 | 9,129 |
MOORE JOHN R | General Counsel | 09/06/2022 | 51,598 |
MOORE JOHN R | General Counsel | 08/03/2022 | 12,325 |
MOORE JOHN R | General Counsel | 08/03/2022 | 85,921 |
MOORE JOHN R | General Counsel | 07/05/2022 | 10,307 |
MOORE JOHN R | General Counsel | 07/06/2022 | 2,019 |
MOORE JOHN R | General Counsel | 07/05/2022 | 68,329 |
MOORE JOHN R | General Counsel | 07/06/2022 | 8,928 |
MOORE JOHN R | General Counsel | 06/16/2022 | 28,413 |
MOORE JOHN R | General Counsel | 06/21/2022 | 43,501 |
MOORE JOHN R | General Counsel | 06/17/2022 | 42,705 |
MOORE JOHN R | General Counsel | 06/21/2022 | 226,695 |
MOORE JOHN R | General Counsel | 06/17/2022 | 146,434 |
MOORE JOHN R | General Counsel | 06/16/2022 | 90,805 |
MOORE JOHN R | General Counsel | 06/13/2022 | 2,906 |
MOORE JOHN R | General Counsel | 06/15/2022 | 13,962 |
MOORE JOHN R | General Counsel | 06/14/2022 | 2,576 |
MOORE JOHN R | General Counsel | 06/15/2022 | 114,020 |
MOORE JOHN R | General Counsel | 06/14/2022 | 21,855 |
MOORE JOHN R | General Counsel | 06/13/2022 | 24,582 |
MOORE JOHN R | General Counsel | 06/08/2022 | 8,922 |
MOORE JOHN R | General Counsel | 06/10/2022 | 5,059 |
MOORE JOHN R | General Counsel | 06/09/2022 | 5,407 |
MOORE JOHN R | General Counsel | 06/10/2022 | 43,120 |
MOORE JOHN R | General Counsel | 06/09/2022 | 49,397 |
MOORE JOHN R | General Counsel | 06/08/2022 | 83,362 |
MOORE JOHN R | General Counsel | 06/07/2022 | 14,054 |
MOORE JOHN R | General Counsel | 06/06/2022 | 26,893 |
MOORE JOHN R | General Counsel | 06/03/2022 | 29,394 |
MOORE JOHN R | General Counsel | 06/07/2022 | 119,702 |
MOORE JOHN R | General Counsel | 06/06/2022 | 84,085 |
MOORE JOHN R | General Counsel | 06/03/2022 | 92,198 |
Carruthers R Michael | Chief Financial Officer | 05/23/2022 | 6,390 |
ORBIMED ADVISORS LLC | Director | 05/18/2022 | 994,980 |
Thompson Peter A. | Director | 05/18/2022 | 994,980 |
MOORE JOHN R | General Counsel | 05/16/2022 | 80,146 |
MOORE JOHN R | General Counsel | 01/21/2022 | 3,834 |
MOORE JOHN R | General Counsel | 12/28/2021 | 3,834 |
Russell Alan J | Chief Scientific Officer | 11/30/2021 | 37,815 |
Russell Alan J | Chief Scientific Officer | 11/15/2021 | 9,155 |
Russell Alan J | Chief Scientific Officer | 11/12/2021 | 167,074 |
Russell Alan J | Chief Scientific Officer | 11/11/2021 | 384,238 |
Russell Alan J | Chief Scientific Officer | 11/10/2021 | 243,170 |
Russell Alan J | Chief Scientific Officer | 11/09/2021 | 594,306 |
Russell Alan J | Chief Scientific Officer | 11/05/2021 | 255,907 |
Russell Alan J | Chief Scientific Officer | 11/04/2021 | 146,092 |
Russell Alan J | Chief Scientific Officer | 11/08/2021 | 181,824 |
Russell Alan J | Chief Scientific Officer | 11/03/2021 | 476,096 |
Russell Alan J | Chief Scientific Officer | 11/02/2021 | 305,360 |
Russell Alan J | Chief Scientific Officer | 11/01/2021 | 8,454 |
Russell Alan J | Chief Scientific Officer | 10/14/2021 | 104,517 |
Russell Alan J | Chief Scientific Officer | 10/15/2021 | 25,966 |
Russell Alan J | Chief Scientific Officer | 10/11/2021 | 22,885 |
Russell Alan J | Chief Scientific Officer | 10/08/2021 | 107,121 |
Russell Alan J | Chief Scientific Officer | 10/07/2021 | 241,614 |
Russell Alan J | Chief Scientific Officer | 10/06/2021 | 38,007 |
Russell Alan J | Chief Scientific Officer | 10/04/2021 | 1,800 |
Russell Alan J | Chief Scientific Officer | 10/01/2021 | 4,932 |
Russell Alan J | Chief Scientific Officer | 10/05/2021 | 98,677 |
Russell Alan J | Chief Scientific Officer | 09/29/2021 | 199,730 |
Russell Alan J | Chief Scientific Officer | 09/28/2021 | 252,753 |
Russell Alan J | Chief Scientific Officer | 09/27/2021 | 208,774 |
Russell Alan J | Chief Scientific Officer | 09/24/2021 | 365,016 |
Russell Alan J | Chief Scientific Officer | 09/23/2021 | 497,632 |
ROOT JONATHAN D | Director | 03/30/2021 | 250,000 |
Thompson Peter A. | Director | 03/30/2021 | 5,750,000 |
ORBIMED ADVISORS LLC | Director | 03/30/2021 | 5,750,000 |
Novo Holdings A/S | 10% Owner | 03/30/2021 | 10,000,000 |
Flynn James E | 10% Owner | 03/30/2021 | 10,000,000 |
Load More Insider Transactions
FUNDS WITH A POSITION IN EDGEWISE THERAPEUTICS INC
Fund | # Shares Owned | % of Portfolio | % Change | Investing Style |
---|---|---|---|---|
ORBIMED ADVISORS LLC | 14,756,096 | 3.24% | 1.30% | Other |
VIKING GLOBAL INVESTORS LP | 6,159,146 | 0.25% | No change | Growth At A Reasonable Price |
DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 3,933,137 | 0.79% | No change | Other |
BlackRock Inc. | 3,505,199 | 0.00159% | 5.99% | Other |
BAKER BROS. ADVISORS LP | 3,112,786 | 0.39% | 196.54% | Other |
GEODE CAPITAL MANAGEMENT, LLC | 947,046 | 0.00108% | 6.2% | Other |
DRIEHAUS CAPITAL MANAGEMENT LLC | 395,069 | 0.05% | New | Growth |
CANDRIAM S.C.A. | 308,000 | 0.02% | 3.36% | Other |
UBS OCONNOR LLC | 114,685 | 0.09% | -18% | Value |
RENAISSANCE TECHNOLOGIES LLC | 64,700 | 0.0011% | -57.15% | Other |
ALPS ADVISORS INC | 43,226 | 0.00372% | -7.78% | Other |
D. E. SHAW & CO., INC. | 31,950 | 0.00031% | New | Other |
CHANGE IN SHARES OUTSTANDING FOR EDGEWISE THERAPEUTICS INC
STOCK BUYBACKS FOR EDGEWISE THERAPEUTICS INC
Period of Report
Previous Period
% Change in Shares
10-K/10-Q Filings
Quarter
Load More
Period of Report: 12/31/2023
10-K/10-Q Filings: View
Previous Period
% Change in Shares
Quarter
09/30/2023
2.09%
1Q
06/30/2023
2.22%
2Q
03/31/2023
2.40%
3Q
12/31/2022
2.29%
4Q
09/30/2022
24.96%
5Q
06/30/2022
30.56%
6Q
03/31/2022
30.76%
7Q
12/31/2021
72.64%
8Q
09/30/2021
31.51%
9Q
06/30/2021
31.52%
10Q
Load More
BUYBACK ANNOUNCEMENT(S) FOR EDGEWISE THERAPEUTICS INC
LOADING...